EBITDA Margin % is calculated as EBITDA divided by its Revenue. aXichem AB's EBITDA for the
three
months ended in Mar. 2026 was €-0.15 Mil. aXichem AB's Revenue for the
three
months ended in Mar. 2026 was €0.36 Mil. Therefore, aXichem AB's EBITDA margin for the quarter that ended in Mar. 2026 was -41.41%.
aXichem AB (FRA:A6X) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
aXichem AB EBITDA Margin % Related Terms
aXichem AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for aXichem AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:A6X vs LIN, SHW, ECL: EBITDA Margin % Comparison
For the Specialty Chemicals subindustry, aXichem AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aXichem AB EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, aXichem AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where aXichem AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aXichem AB (FRA:A6X) has a EBITDA Margin % of -41.41% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on aXichem AB and its competitors. According to the industry distribution chart, aXichem AB ranks #1508 out of 1580 companies in the Chemicals industry, placing it in the top 95.4%.
Is aXichem AB's EBITDA Margin % too high?
aXichem AB's current EBITDA Margin % is -41.41%. Based on the distribution chart, aXichem AB ranks #1508 out of 1580 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, aXichem AB has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does aXichem AB's EBITDA Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, aXichem AB ranks #1508 out of 1580 companies for EBITDA Margin %. This places aXichem AB in the lower half of its industry. The industry median EBITDA Margin % is 9.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.63, based on 1,580 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on aXichem AB and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aXichem AB's current EBITDA Margin % is -41.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aXichem AB stock overvalued right now?
aXichem AB (FRA:A6X) has a current EBITDA Margin % of -41.41%. The stock's GF Value™ is €0.22, compared to a current price of €0.10 — trading 53.2% below its estimated fair value. The current EBITDA Margin % is -41.41%. aXichem AB's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For aXichem AB (FRA:A6X), the current EBITDA Margin % is -41.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aXichem AB (FRA:A6X) Overvalued in 2026?
Based on GuruFocus' analysis, aXichem AB stock appears to be undervalued.
The current stock price of €0.10 is trading 53.2% below its estimated GF Value™ of €0.22.
Key valuation signals for FRA:A6X:
EBITDA Margin %: -41.41%
GF Value™: €0.22 vs. price of €0.10 (53.2% below fair value)
No single metric tells the full story. See the FRA:A6X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aXichem AB develops, patents, markets and sells natural analogue industrial chemicals, which are synthetically produced substances with similar and comparable properties to natural substances. The Company's business concept is to develop, patent, market and sell natural analogue industrial chemicals. Its commercial focus is on the proprietary patented product phenylcapsaicin, the Company's first product, which is marketed under the registered trademarks aXiphen as an additive in animal feed and aXivite as an ingredient in food supplements and as a bioenhancer. The Company's product portfolio comprises Phenylcapsaicin, aXiphen, aXiphen bio, and aXivite. The Company's focus is on establishing aXiphen as an additive in poultry feed and pig feed.
50GF Score
Get the complete analysis for FRA:A6X
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A6X has been successfully added to your 
